Our portfolio company Vaccibody has released an update on the clinical trial of their neoantigen cancer vaccine in phase I/II: 10 patients have been enrolled and vaccination has started.
Mads Axelsen, MD, Chief Medical Officer in Vaccibody, said in a press release:
“We are very pleased with the enrollment in the neoantigen trial and with the interest we are experiencing from clinical investigator and from patients. To that end I would like to thank the experienced cancer experts and investigators in this trial namely Prof. Jürgen Krauss from Heidelberg, Prof. Angela Krackhardt from Munich and Prof. Elke Jäger from Frankfurt. Together with their dedicated teams they are doing an outstanding job with the neoantigen trial.”